Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors fof COVID-19
On Apr. 2, 2020, Vir Biotech and Alnylam Pharma announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for SARS-CoV-2.
This expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry.
Tags:
Source: Alnylam Pharmaceuticals, Inc.
Credit:
